CMBA
FLGT icon

C.M. Bidwell & Associates’s Fulgent Genetics FLGT Stock Holding History

C.M. Bidwell & Associates’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,065
Closed -$107K – 563
2021
Q4 		$107K Buy
+1,065
New +$93.6K 0.07% 238

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

C.M. Bidwell & Associates's FLGT Position: Q1 2022 in Review

C.M. Bidwell & Associates sold out of Fulgent Genetics (FLGT) in Q1 2022, closing a stake of 1,065 shares — an estimated $107K sold.

C.M. Bidwell & Associates first reported a position in FLGT in Q4 2021 and held it in 1 quarter. The position peaked at $107K in Q4 2021. 275 funds tracked by Wall St. Rank hold FLGT as of Q1 2022.

  • C.M. Bidwell & Associates reported no remaining Fulgent Genetics position as of Q1 2022 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 1,065 Fulgent Genetics shares in Q1 2022, an estimated $107K.
  • C.M. Bidwell & Associates first reported a position in Fulgent Genetics in Q4 2021 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Fulgent Genetics position peaked at $107K in Q4 2021.
  • 275 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2022.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2022, filed 29 Apr 2022.